Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label spesolimab in ulcerative colitis (extension of prior BI 655130 trials)
jRCT2080224139Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in autoimmune colitis, sponsored by Boehringer Ingelheim. Primary endpoint: Primary safety endpoint. Started Nov 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224139.